Integral Diagnostics Limited

ASX IDX.AX

Integral Diagnostics Limited Net Cash Used Provided By Financing Activities for the year ending June 30, 2024: USD -19.64 M

Integral Diagnostics Limited Net Cash Used Provided By Financing Activities is USD -19.64 M for the year ending June 30, 2024, a 7.34% change year over year. Net cash used/provided by financing activities are the total cash inflows and outflows related to activities that finance the company’s operations, including debt, equity, and dividends.

Integral Diagnostics Limited Net Cash Used Provided By Financing Activities for the year ending June 30, 2023 was USD -21.20 M, a -137.85% change year over year.
Integral Diagnostics Limited Net Cash Used Provided By Financing Activities for the year ending June 30, 2022 was USD 55.99 M, a 1,053.26% change year over year.
Integral Diagnostics Limited Net Cash Used Provided By Financing Activities for the year ending June 30, 2021 was USD -5.87 M, a -111.29% change year over year.
Integral Diagnostics Limited Net Cash Used Provided By Financing Activities for the year ending June 30, 2020 was USD 52.05 M, a 20.46% change year over year.

Key data

Date	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure	Effect Of Forex Changes On Cash

ASX: IDX.AX

Integral Diagnostics Limited

CEO	Dr. Ian Kadish M.B.A., MBBCh
IPO Date	Oct. 20, 2015
Location	Australia
Headquarters	45 William Street
Employees	1,977
Sector	Health Care
Industries Hospitals & Clinics Medical Instruments Professional Services Telehealth

Description

Integral Diagnostics Limited, a healthcare services company, provides diagnostic imaging services to general practitioners, medical specialists, and allied health professionals and their patients in Australia and New Zealand. It provides services through 67 radiology clinics. The company was incorporated in 2008 and is headquartered in Melbourne, Australia.

Key trends

Past 5 years